What is the current Price Target for the Trevi Therapeutics, Inc. stock?

The average Trevi Therapeutics, Inc. target price is $19.05. This is 206.20% higher than the current stock price. The highest price target is 366.24%, the lowest is 76.85%. 11 Analysts have issued a price target Trevi Therapeutics, Inc. 2026 .

How high will the Trevi Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Trevi Therapeutics, Inc. stock will rise. The performance of stocks, including the Trevi Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Trevi Therapeutics, Inc. stock today?

The performance of Trevi Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Trevi Therapeutics, Inc. stock fall?

The decline in Trevi Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Trevi Therapeutics, Inc. Forecast, price target & analysts

$6.00

3.54% today

Nasdaq, Apr 04, 07:48 pm CET

ISIN

US89532M1018

Symbol

TRVI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Trevi Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Trevi Therapeutics, Inc. Classifications & Recommendation:

Buy

100%

Trevi Therapeutics, Inc. Price Target

Target Price	$19.05
Price	$6.22
Potential	206.20% register free of charge
Number of Estimates	11

	11 Analysts have issued a price target Trevi Therapeutics, Inc. 2026 . The average Trevi Therapeutics, Inc. target price is $19.05. This is 206.20% register free of charge higher than the current stock price. The highest price target is $29.00 366.24% register free of charge , the lowest is $11.00 76.85% register free of charge .
	A rating was issued by 11 analysts: 11 Analysts recommend Trevi Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Trevi Therapeutics, Inc. stock has an average upside potential 2026 of 206.20% register free of charge . Most analysts recommend the Trevi Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.47	-0.52
	62.07%	10.64%
P/E		negative

6 Analysts have issued a Trevi Therapeutics, Inc. forecast for earnings per share. The average Trevi Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.47	62.07%
2025	$-0.52 10.64% Unlock
2026	$-0.58 11.54% Unlock
2027	$-0.59 1.72% Unlock
2028	$-0.20 66.10% Unlock
2029	$0.65 425.00% Unlock

Current	-13.23	12.50%
2025	-12.08 8.69% Unlock
2026	-10.66 11.75% Unlock
2027	-10.63 0.28% Unlock
2028	-31.90 200.09% Unlock
2029	9.61 130.13% Unlock

Trevi Therapeutics, Inc....

Current Trevi Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
B. Riley Securities	Locked ➜ Locked	Locked	Mar 19 2025
D. Boral Capital	Locked ➜ Locked	Locked	Mar 19 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 19 2025
Needham	Locked ➜ Locked	Locked	Mar 19 2025
Oppenheimer	Locked ➜ Locked	Locked	Mar 11 2025
D. Boral Capital	Locked ➜ Locked	Locked	Mar 10 2025
Raymond James	Locked ➜ Locked	Locked	Mar 10 2025

Analyst Rating	Date
Locked B. Riley Securities: Locked ➜ Locked	Mar 19 2025
Locked D. Boral Capital: Locked ➜ Locked	Mar 19 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 19 2025
Locked Needham: Locked ➜ Locked	Mar 19 2025
Locked Oppenheimer: Locked ➜ Locked	Mar 11 2025
Locked D. Boral Capital: Locked ➜ Locked	Mar 10 2025
Locked Raymond James: Locked ➜ Locked	Mar 10 2025

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now